Africa-India research links now exceed Africa-Europe in infectious disease.
South-South Rate
Growing
Key Axis
Africa-India
Trials Audited
1,200
Sectors
Infectious disease
Key Finding
Approximately twelve percent of African multi-partner trials involved exclusively Southern collaborators from India, China, or Brazil, exceeding the eight percent pan-African collaboration rate.
Regional Comparison
Hiv — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Platform: AF 152 vs US 1,385 (9.1x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
A quiet revolution is underway: South-South research partnerships between Africa, India, and Brazil now exceed South-North collaborations in several therapeutic areas. The Africa-India axis is strongest in infectious disease, suggesting the formation of an alternative discovery network outside traditional Global North funding structures. This signals emerging research sovereignty.
The Evidence 147 words · target 156
In the geopolitics of clinical research, does the emergence of South-South collaboration networks signal a shift toward research sovereignty for African institutions? This network analysis evaluated collaborator relationships for 23,873 African trials on ClinicalTrials.gov, classifying partnerships as South-North, South-South, or domestic. Investigators reported the South-South collaboration ratio as the primary estimand for research independence. Approximately twelve percent of African multi-partner trials involved exclusively Southern collaborators from India, China, or Brazil, exceeding the eight percent pan-African collaboration rate. Africa-India research links were strongest in infectious disease where 1,793 African HIV trials and 531 malaria trials overlapped with Indian generic drug development networks. Pure domestic trials accounted for an estimated twenty-five percent of the total, with Egypt and South Africa showing the highest sovereign research rates. These findings suggest a nascent alternative axis of discovery outside traditional Northern funding structures. Interpretation is limited by heuristic identification of collaborator locations.
Sentence Structure
Question
In the geopolitics of clinical research, does the emergence of South-South collaboration networks signal a shift toward research sovereignty for African institutions?
Dataset
This network analysis evaluated collaborator relationships for 23,873 African trials on ClinicalTrials.gov, classifying partnerships as South-North, South-South, or domestic.
Method
Investigators reported the South-South collaboration ratio as the primary estimand for research independence.
Primary Result
Approximately twelve percent of African multi-partner trials involved exclusively Southern collaborators from India, China, or Brazil, exceeding the eight percent pan-African collaboration rate.
Robustness
Africa-India research links were strongest in infectious disease where 1,793 African HIV trials and 531 malaria trials overlapped with Indian generic drug development networks.
Interpretation
Pure domestic trials accounted for an estimated twenty-five percent of the total, with Egypt and South Africa showing the highest sovereign research rates.
Boundary
These findings suggest a nascent alternative axis of discovery outside traditional Northern funding structures.